Goldman Sachs’s Minerva Neurosciences NERV Stock Holding History

Goldman Sachs’s Portfolio NERV Stock Details NERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$193K	Buy	+32,012	New	+$184K	﹤0.01%	6096
2021 Q4	–	Sell	-4,195	Closed	-$58K	–	6619
2021 Q3	$58K	Sell	4,195 -8,001	-66%	-$120K	﹤0.01%	6014
2021 Q2	$227K	Sell	12,196 -107,291	-90%	-$2.31M	﹤0.01%	5685
2021 Q1	$2.79M	Sell	119,487 -4,405	-4%	-$110K	﹤0.01%	3655
2020 Q4	$2.32M	Sell	123,892 -22,822	-16%	-$575K	﹤0.01%	3620
2020 Q3	$3.73M	Buy	146,714 +52,540	+56%	+$1.42M	﹤0.01%	3123
2020 Q2	$2.72M	Buy	94,174 +81,446	+640%	+$4.78M	﹤0.01%	3241
2020 Q1	$613K	Buy	12,728 +2,225	+21%	+$134K	﹤0.01%	4093
2019 Q4	$597K	Sell	10,503 -253	-2%	-$11.2K	﹤0.01%	4405
2019 Q3	$666K	Buy	10,756 +1,373	+15%	+$77.8K	﹤0.01%	4294
2019 Q2	$423K	Sell	9,383 -3,493	-27%	-$175K	﹤0.01%	4467
2019 Q1	$809K	Sell	12,876 -1,526	-11%	-$91.7K	﹤0.01%	4174
2018 Q4	$777K	Buy	14,402 +1,485	+11%	+$109K	﹤0.01%	4114
2018 Q3	$1.3M	Buy	12,917 +7,066	+121%	+$531K	﹤0.01%	3889
2018 Q2	$386K	Buy	5,851 +2,691	+85%	+$163K	﹤0.01%	4653
2018 Q1	$158K	Sell	3,160 -1,944	-38%	-$93.4K	﹤0.01%	5111
2017 Q4	$247K	Buy	5,104 +1,649	+48%	+$81.8K	﹤0.01%	5298
2017 Q3	$210K	Sell	3,455 -932	-21%	-$53.5K	﹤0.01%	5720
2017 Q2	$311K	Sell	4,387 -351	-7%	-$22.7K	﹤0.01%	5478
2017 Q1	$307K	Sell	4,738 -1,404	-23%	-$109K	﹤0.01%	5444
2016 Q4	$577K	Buy	6,142 +4,856	+378%	+$496K	﹤0.01%	4926
2016 Q3	$145K	Buy	+1,286	New	+$125K	﹤0.01%	6025
2016 Q2	–	Sell	-5,598	Closed	-$275K	–	7168
2016 Q1	$275K	Buy	5,598 +1,547	+38%	+$66.1K	﹤0.01%	5343
2015 Q4	$197K	Sell	4,051 -2,039	-33%	-$85.1K	﹤0.01%	5727
2015 Q3	$256K	Buy	6,090 +287	+5%	+$13.2K	﹤0.01%	5751
2015 Q2	$269K	Buy	5,803 +2,090	+56%	+$89.2K	﹤0.01%	5853
2015 Q1	$149K	Sell	3,713 -16	-0.4%	-$662	﹤0.01%	6212
2014 Q4	$180K	Sell	3,729 -2,055	-36%	-$78.4K	﹤0.01%	6239
2014 Q3	$280K	Buy	+5,784	New	+$307K	﹤0.01%	5824

Other funds holding NERV

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

FCMV

Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

SSC

Spruce Street Capital New York $416M AUM

Goldman Sachs's NERV Position: Q1 2026 in Review

Goldman Sachs opened a new position in Minerva Neurosciences (NERV) in Q1 2026: 32,012 shares worth $193K. The stake represents ﹤0.01% of the portfolio and ranks #6096 among its holdings. This is a return to the name: Goldman Sachs previously reported a position in NERV as recently as Q3 2021.

Goldman Sachs first reported a position in NERV in Q3 2014 and has held it in 29 quarters since. The position peaked at $3.73M in Q3 2020. 47 funds tracked by Wall St. Rank hold NERV as of Q1 2026.

Goldman Sachs held 32,012 shares of Minerva Neurosciences worth $193K as of Q1 2026.
Minerva Neurosciences was a new Goldman Sachs position in Q1 2026.
Minerva Neurosciences made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #6096 holding.
Goldman Sachs first reported a position in Minerva Neurosciences in Q3 2014 and has held it in 29 quarters since.
Goldman Sachs's Minerva Neurosciences position peaked at $3.73M in Q3 2020.
47 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.